Andrew Joseph Muir, MD

Professor of Medicine
Chief, Division of Gastroenterology in the Department of Medicine
Member in the Duke Clinical Research Institute
Campus mail 03137B Hosp South, Durham, NC 27710
Phone (919) 684-2052
Email address
  • Hepatitis C 
  • Primary sclerosing cholangitis
  • Cirrhosis
  • Liver Transplantation
  • Clinical Trials
  • Healthcare disparities in liver disease 
  • Outcomes Research

Education and Training

  • Fellow in Gastroenterology, Medicine, Duke University, 1998 - 2000
  • Chief Medical Resident, Medicine, Duke University, 1997 - 1998
  • Fellow in Gastroenterology, Medicine, Duke University, 1996 - 1997
  • Medical Resident, Medicine, Duke University, 1993 - 1996
  • M.H.S., Duke University, 2001
  • M.D., Duke University, 1993


Muir, Andrew J. “Is Magnetic Resonance Cholangiopancreatography Worth a Thousand Words in Determining Prognoses of Patients With Primary Sclerosing Cholangitis?.” Clin Gastroenterol Hepatol, May 8, 2019.

Full Text

Sanyal, Arun J., Stephen A. Harrison, Vlad Ratziu, Manal F. Abdelmalek, Anna Mae Diehl, Stephen Caldwell, Mitchell L. Shiffman, et al. “The Natural History of Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: Data From the Simtuzumab Trials..” Hepatology, April 16, 2019.

Full Text

Younossi, Zobair M., Maria Stepanova, Ira Jacobson, Andrew J. Muir, Stanislas Pol, Stefan Zeuzem, Ziad Younes, et al. “Not Achieving Sustained Viral Eradication of Hepatitis C Virus After Treatment Leads to Worsening of Patient-Reported Outcomes..” Clin Infect Dis, April 5, 2019.

Full Text

Hirschfield, Gideon M., Olivier Chazouillères, Joost P. Drenth, Douglas Thorburn, Stephen A. Harrison, Charles S. Landis, Marlyn J. Mayo, et al. “Effect of NGM282, an FGF19 analogue, in primary sclerosing cholangitis: A multicenter, randomized, double-blind, placebo-controlled phase II trial..” J Hepatol 70, no. 3 (March 2019): 483–93.

Full Text

Muir, Andrew J., Cynthia Levy, Harry L. A. Janssen, Aldo J. Montano-Loza, Mitchell L. Shiffman, Stephen Caldwell, Velimir Luketic, et al. “Simtuzumab for Primary Sclerosing Cholangitis: Phase 2 Study Results With Insights on the Natural History of the Disease..” Hepatology 69, no. 2 (February 2019): 684–98.

Full Text

Bailey, D. E., A. J. Muir, J. A. Adams, N. M. Thygeson, H. Williams, M. P. Cary, and R. A. Anderson. “Clinical Encounters and Treatment Initiation for Chronic Hepatitis C Patients: Applications of Adaptive Leadership Framework for Chronic Illness.” Sage Open 9, no. 1 (January 1, 2019).

Full Text

Younossi, Zobair, Maria Stepanova, Arun J. Sanyal, Stephen A. Harrison, Vlad Ratziu, Manal F. Abdelmalek, Anna Mae Diehl, et al. “The conundrum of cryptogenic cirrhosis: Adverse outcomes without treatment options..” J Hepatol 69, no. 6 (December 2018): 1365–70.

Full Text

Patel, Yuval A., Jacqueline B. Henson, Julius M. Wilder, Jiayin Zheng, Schein-Chung Chow, Carl L. Berg, Stuart J. Knechtle, and Andrew J. Muir. “The impact of human leukocyte antigen donor and recipient serotyping and matching on liver transplant graft failure in primary sclerosing cholangitis, autoimmune hepatitis, and primary biliary cholangitis..” Clin Transplant 32, no. 10 (October 2018).

Full Text

Kappus, Matthew R., Kara Wegermann, Katie Charles, Yuval Patel, Gemini Janas, Erol Bozdogan, Alice Parish, Donna Niedzwiecki, Andrew Joseph Muir, and Mustafa Bashir. “Use of Skeletal Muscle Index As a Predictor of Waitlist Mortality in Patients with End-Stage Liver Disease.” In Hepatology, 68:658A-659A. WILEY, 2018.


Muir, Andrew Joseph, Jia Yao, Julius Wilder, Christina Makarushka, Kelly Keefe, James Henry Helzberg, Paolo Mannelli, et al. “The Alcohol Use Disorders Identification Test Screening in Patients with Hepatitis C.” In Hepatology, 68:908A-908A. WILEY, 2018.